Top Markets
#1 Pleasing Gold Pleasing Gold +1,500.40%
#2 PulseChain PulseChain +58.12%
#3 Ontology Gas Ontology Gas +39.03%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.89%
#5 BOOK OF MEME BOOK OF MEME +32.67%
#6 ConstitutionDAO ConstitutionDAO +28.49%
#7 Pump.fun Pump.fun +26.06%
#8 Unit Pump Unit Pump +26.06%
#9 Neiro Neiro +25.54%
#10 Nockchain Nockchain +22.01%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

ARPO
Rangering i aksjer #26440
Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in... Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.
Aksjekurs
$2.20
Sist synkronisert: 2021-08-26
Markedsverdi
$40.53M
Endring (1 dag)
-0.90%
Endring (1 år)
0.00%
Land
US
Handel Aerpio Pharmaceuticals, Inc. (ARPO)

Kategori

Healthcare
P/E-forhold for Aerpio Pharmaceuticals, Inc. (ARPO)
P/E-forhold per 2026 TTM: 0
Ifølge Aerpio Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Aerpio Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.